FDA approves Sunharbo, first factor XIa inhibitor, for secondary stroke prevention
In the 12,327-patient OCEANIC-STROKE trial, the 50 mg daily dose cut ischemic stroke risk 26% versus placebo, with more major bleeding in patients older than 75.
Key takeaways
- The FDA on November 9, 2026 approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa inhibitor, for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA.
- The drug is taken with antiplatelet therapy and, in a 12,327-patient trial, reduced ischemic stroke risk 26% versus placebo over a median 14.2 months.
- Major bleeding was higher with Sunharbo in patients older than 75 years and in the first 90 days, and gastrointestinal bleeding was more common than with placebo.
- The label says the drug is to be held at least 24 hours after thrombolysis for acute ischemic stroke and is not approved for patients with atrial fibrillation.
- For crews: the approval went to Bayer HealthCare Pharmaceuticals; the FDA record lists no reversal agent, launch date or price.
The U.S. Food and Drug Administration approved Sunharbo (asundexian) 50 mg tablets on November 9, 2026, according to an FDA news release issued the same day [1]. The agency describes the drug as the first factor XIa inhibitor to reach the U.S. market [1].
The approval covers adults who have had a recent mild-to-moderate ischemic stroke not caused by a clot from the heart, or a high-risk transient ischemic attack (TIA) [1]. The drug is taken together with antiplatelet therapy to lower the risk of a further stroke [1].
The approval went to Bayer HealthCare Pharmaceuticals Inc. of Whippany, N.J. [1]. The FDA said it had given the application Fast Track and Priority Review designations [1].
What the records show
The FDA based its effectiveness finding on a phase 3 trial called OCEANIC-STROKE [1]. The release describes it as multicenter, randomized, double-blind and placebo-controlled, with 12,327 adults enrolled [1].
Participants had a recent non-cardioembolic ischemic stroke with an NIH Stroke Scale score of 15 or less, or a high-risk TIA [1]. They were assigned to Sunharbo or placebo within 72 hours of symptom onset, and both arms received antiplatelet therapy [1].
Over a median treatment period of 14.2 months, the 50 mg once-daily dose cut the risk of ischemic stroke by 26% compared with placebo, according to the release [1]. The release does not give the number of strokes in each arm.
On safety, the FDA said the overall rate of major bleeding was similar in the two groups [1]. Major bleeding was higher with Sunharbo in patients older than 75 years and during the first 90 days of treatment [1]. Gastrointestinal bleeding was more common with the drug than with placebo [1]. Diarrhea was the most frequently reported adverse reaction, occurring in 3% or more of treated patients [1].
The release lists several restrictions in the labeling [1]:
- The label advises against combining the drug with medicines that are both P-gp inducers and strong CYP3A4 inducers, with carbamazepine given as the example, because they may lower its effectiveness [1].
- Patients with moderate or severe liver impairment are not recommended to receive it [1].
- Patients are to stop it at least 24 hours ahead of elective surgery or an invasive procedure [1].
- After thrombolysis for an acute ischemic stroke, a hold of at least 24 hours also applies [1].
- The drug is not approved for stroke prevention in patients with atrial fibrillation [1].
Hylton V. Joffe, M.D., who heads the Office of Cardiology, Hematology, Endocrinology, and Nephrology at the FDA's drug center, said in the release that stroke "survivors are at risk of having another stroke" [1]. Joffe called the approval "a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention" [1].
Why it matters for clinicians
Stroke and TIA patients are routine for EMS crews and emergency departments, and the new label reaches into that setting. The FDA says the drug is to be held for at least 24 hours after thrombolysis for acute ischemic stroke [1]. A patient on Sunharbo for a prior stroke who presents with a new one will therefore be taking a factor XIa inhibitor at the time a thrombolysis decision is made. The release does not describe a reversal agent or a bedside test for the drug.
The approval also adds a new drug class to the medication lists clinicians will see. Patients on Sunharbo are also on antiplatelet therapy under the approved use [1]. The bleeding signal the FDA reported concentrates in patients older than 75 years and in the first 90 days of treatment, and gastrointestinal bleeding was more common with the drug [1]. Those are the patients, and the window, in which bleeding complaints would be expected to surface.
The FDA noted that the drug is not approved for patients with atrial fibrillation [1]. Stroke patients whose clots originate in the heart fall outside this approval, per the release [1]. EMS clinicians follow local protocols and medical direction on stroke and anticoagulation questions.
What the records do not tell us
- The release gives a 26% relative reduction in ischemic stroke but no absolute event rates, no per-arm counts and no confidence interval [1].
- It does not report deaths, disability outcomes or the rate of hemorrhagic stroke in the trial.
- It does not say how many participants were enrolled in the United States or how many countries took part.
- It does not describe any reversal agent, laboratory monitoring or guidance for emergency bleeding management.
- It does not give a price, a launch date or when pharmacies will stock the drug.
- The full prescribing information and a peer-reviewed publication of OCEANIC-STROKE are not among the records reviewed here, and Bayer has not commented in these records.
Questions readers ask
What is Sunharbo (asundexian) approved for?
The FDA approved Sunharbo 50 mg tablets on November 9, 2026, for use with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk TIA. It is not approved for stroke prevention in patients with atrial fibrillation.
How well did asundexian work in the OCEANIC-STROKE trial?
In a randomized, double-blind, placebo-controlled trial of 12,327 adults, Sunharbo 50 mg once daily reduced the risk of ischemic stroke by 26% compared with placebo over a median treatment of 14.2 months, according to the FDA.
What are the bleeding risks with Sunharbo?
The FDA said overall major bleeding was similar to placebo but was increased in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding was more common with Sunharbo, and diarrhea was the most frequently reported adverse reaction.
Who makes Sunharbo and what kind of drug is it?
Sunharbo is the first factor XIa inhibitor approved by the FDA. The approval was granted to Bayer HealthCare Pharmaceuticals Inc. of Whippany, N.J., with Fast Track and Priority Review designations.
Sources
- FDA News Release: FDA Approves First Factor XIa Inhibitor to Help Prevent Stroke in Certain Adults at High Risk (Nov. 9, 2026) — fda.gov (2026-11-09). fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-
This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.


